Business

Johnson & Johnson recently announced plans to pay $6.5 billion over 25 years to settle the majority of the lawsuits in the U.S. alleging that its talc-based products caused ovarian cancer. This move comes after years of financial and public relations challenges for the company, which has long maintained that its talc products are safe
0 Comments
In a recent development, a federal judge in New Jersey has issued a ruling rejecting the legal challenges made by Johnson & Johnson and Bristol Myers Squibb against the Biden administration’s Medicare drug price negotiations. This decision marks a significant win for the Biden administration in its efforts to make medications more affordable for seniors.
0 Comments
In a move reminiscent of a high-stakes drama on “Succession,” Paramount Global is gearing up to oust CEO Bob Bakish in a strategic maneuver set to reshape the company’s future. This pivotal decision is set to take place on Monday, just before the company announces its earnings post-market close. The objective behind this dramatic move
0 Comments
The Food and Drug Administration recently approved Pfizer’s treatment for a rare genetic bleeding disorder, marking a significant milestone for the company. This groundbreaking gene therapy, known as Beqvez, is the first of its kind to receive clearance in the United States. The approval opens up new possibilities for adults with moderate to severe hemophilia
0 Comments
Walgreens recently announced a significant expansion of its specialty pharmacy services by launching a new business unit dedicated to bringing cell and gene therapies directly to U.S. patients. This move comes as chronic diseases continue to rise, necessitating specialized medications that require careful handling and distribution. Impact of Specialty Pharmacies Specialty pharmacies have become a
0 Comments
PepsiCo recently released its quarterly earnings and revenue, surpassing analysts’ expectations despite facing challenges such as weaker U.S. demand due to recalls and backlash over increased prices. The company reported earnings per share of $1.61, higher than the expected $1.52, and revenue of $18.25 billion, exceeding the anticipated $18.07 billion. Impact of Quaker Oats Recalls
0 Comments